Vital Therapies seeks $86.25m for cell therapy via artificial liver
This article was originally published in Clinica
Executive Summary
Vital Therapies said in September that a multi-tranche $76m venture funding commitment would fund the Phase III program for its human allogeneic cellular therapy for the treatment of acute liver failure (www.clinica.co.uk, 1 October 2012). Now the San Diego-based company is seeking up to $86.25m in an initial public offering to complete three late-stage clinical trials for its stem cell-based, bio-artificial liver therapy called ELAD.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.